Trastuzumab containing regimens are the backbone for the treatment of human epidermal growth factor Receptor 2 (HER2)‐positive breast cancer, providing significant clinical benefit for metastatic breast cancer and increasing the proportion of cured patients in the adjuvant setting for early breast cancer.1, 2. The gene discussed is ERBB2; the disease is breast carcinoma.